alengo/E+ via Getty Images Topline Summary Compass Therapeutics (NASDAQ:CMPX) is an oncology-focused developmental biotech working on novel immunotherapies to treat different forms of solid tumor, with the most notable shots on goal being in the gastrointestinal cancers space. They have experienced significant declines in valuation through 2023 and 2024, despite being deep in late-stage clinical study. So today I want to take a look at their projects, what they've shared to date, and the outlook for potenti ...